Follow-up data from the landmark Diabetes Prevention Study examined the role of physical activity in diabetes prevention.
This slideshow highlights several studies regarding the effects of SGLT2 inhibitors, which were presented at the 2016 ADA Scientific Sessions.
Several studies presented at ADA 2016 discussed going beyond basal insulin treatments for patients with type 2 diabetes.
A secondary analysis of data from the Insulin Resistance Intervention after Stroke trial (IRIS) examined pioglitazone’s effect on diabetes prevention.
The first at-home study to test the efficacy & safety of a fully automated, dual hormone (glucagon and insulin) bionic pancreas was presented at ADA.
A study tested the impact of intensive lifestyle intervention in low-income African Americans with type 2 diabetes. Results were shared at ADA.
A post hoc analysis delved further into the EXAMINE trial to evaluate the risk of cardiovascular death in all of the type 2 diabetic participants.
Is health-related quality of life as important as a patient’s A1c? Presentations at the 2016 ADA meeting discussed this component of diabetes care.
Two approaches to replace deteriorating beta cells in patients with type 1 diabetes were presented at the ADA’s Scientific Sessions.